Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326974 · ClinicalTrials.gov registry record · Phase 2
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
A Phase 2 study of Breast Cancer and Stage II Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
- 4
- Study locations
NCT02326974 is a Phase 2 study of Breast Cancer and Stage II Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 164 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT02326974, a Phase 2 study of Breast Cancer and Stage II Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2. The names of the study interventions involved in this study are: * Trastuzumab emtansine (also called T-DM1) * Pertuzumab
Conditions Studied
Interventions
- DRUG T-DM1
- DRUG Pertuzumab
- PROCEDURE Excision of tumor/mastectomy
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Tennessee
- Tennessee Oncology/Sarah Cannon Research Institute - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2015-01 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02326974
The ClinicalTrials.gov registry entry for NCT02326974 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which T-DM1 is the first listed.
NCT02326974 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Tennessee.
Frequently Asked Questions
What is clinical trial NCT02326974 about?
NCT02326974 is a clinical study titled "T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA". This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2. The names of the study interventions involved in this study are: * Trastuzumab emtansine (also called T-DM1) * Pertuzumab
What is the current status of trial NCT02326974?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2015-01. Estimated completion is 2028-01.
What conditions does trial NCT02326974 study?
This clinical trial studies the following conditions: Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Her 2 Positive Breast Cancer.
What interventions are being tested in trial NCT02326974?
The interventions under investigation include: T-DM1 (DRUG), Pertuzumab (DRUG), Excision of tumor/mastectomy (PROCEDURE).
Who is sponsoring clinical trial NCT02326974?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02326974 being conducted?
This trial has 4 study locations across Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.